Engflag

Dopar

Quick links to important sections

Dopar

Dopar_EN

Method of action: Adrenomimetic, Cardiac Therapy, Cardiostimulating, Diuretic, Hypertensive, Vasodilator

Treatment option: Renal Failure, Heart Attack, Surgery, Shock

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dopar

Defining Dopar: What is This Medication?

Property Description
Active Ingredient Levodopa (L-Dopa)
Pharmacological Class Dopamine Precursor, Antiparkinson Agent
Typical Form Oral tablet or capsule
Common Use Management of Parkinson's Disease symptoms
Rx Status Prescription Only

Dopar is the brand name of a prescription medication containing the single active ingredient levodopa (L-Dopa), which is a compound essential for treating Parkinson's disease. While the original Dopar brand is generally discontinued, the International Nonproprietary Name (INN), levodopa, remains the pharmacological gold standard for this condition.

Levodopa’s Composition and Classification

Dopar is categorized as a dopaminergic antiparkinsonism agent and acts as a precursor to dopamine. The active ingredient, levodopa, is a chemically synthesized amino acid that must be prescribed due to its specialized action on the central nervous system. Unlike dopamine itself, levodopa is able to cross the blood-brain barrier (BBB). Once it has crossed the barrier, the body converts it into dopamine, supplementing the low levels associated with the disease.

To ensure efficacy, levodopa is commonly formulated with a second medication, a peripheral decarboxylase inhibitor, to prevent its premature breakdown in the body. This co-formulation ensures that the largest possible amount of the active ingredient is delivered to the brain where it is needed most to address symptoms.

Primary Therapeutic Purpose

The overarching therapeutic purpose of levodopa-based medications is to provide targeted dopamine replacement therapy to control the primary motor symptoms of Parkinson's disease. These medications are used to alleviate difficulties such as bradykinesia (slowness of movement), rigidity (stiffness), and tremors. The goal of this treatment is to help restore motor function and significantly improve a patient's functional abilities and quality of life.

Regulatory References

  1. NIH: Levodopa (L-Dopa) - StatPearls

What side effects are possible with Dopar?

Official Classification of Possible Adverse Effects

The safety profile of levodopa-containing medications is categorized according to the official System Organ Classes (SOCs) and frequency terminology established by regulatory authorities. The appearance and intensity of adverse reactions are often linked to the duration of exposure and the individual patient's underlying condition.

Adverse reactions classified as very common (may affect more than 1 in 10 people) typically involve the nervous system and the gastrointestinal system, with frequently documented effects including dyskinesia (involuntary, abnormal movements) and nausea. Effects listed as common include vomiting, orthostatic hypotension (a drop in blood pressure upon standing, leading to dizziness), general dizziness, sleepiness, insomnia, and the occurrence of hallucinations or confusion.

Documented Serious Adverse Reactions and Safety Patterns

Regulatory documentation identifies several safety considerations that may be of a serious nature. Serious psychiatric disorders such as psychosis are listed, and the medication is typically used with caution in individuals with pre-existing severe psychiatric conditions. In the cardiovascular system, serious adverse reactions have included cardiac arrhythmias and myocardial infarction.

Safety is also contextual: Motor fluctuations and severe dyskinesias are associated with long-term exposure, while effects like nausea and orthostatic hypotension are often observed at the initiation of treatment or during dose escalation. Official labeling mandates caution in patients with conditions like narrow-angle glaucoma or a history of malignant melanoma, which are listed as explicit safety restrictions. Additionally, older adults may exhibit increased sensitivity to certain central adverse effects, such as confusion or hallucinations.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory information for levodopa (Dopar) overdose focuses on specific clinical manifestations and mandated emergency actions. Overexposure may present as an exaggeration of dopaminergic activity, primarily involving the central nervous system and the cardiovascular system. Documented manifestations include dyskinesias, which are involuntary movements, and blepharospasm, often cited as an early sign of excess dosage. Cardiovascular effects may involve sinus tachycardia and other cardiac irregularities or arrhythmias, along with marked hypotension and accompanying symptoms like agitation and mental confusion.

Urgent medical attention is required for any severe manifestation. The most serious outcome documented by regulators is the onset of a symptom complex resembling Neuroleptic Malignant Syndrome (NMS), which is characterized by hyperpyrexia, muscular rigidity, and altered consciousness. This condition, also associated with rapid dose reduction, mandates hospitalization and immediate medical monitoring.

In the event of an overdose, regulatory documents state that no specific antidote is known. Therefore, management is limited to symptomatic and supportive treatment. Patients with a history of heart conditions, such as myocardial infarction with residual arrhythmias, require especially close monitoring of cardiac function in a specialized care setting. Prolonged observation may be necessary, particularly with extended-release formulations.

Therapeutic Uses of Dopar

What Dopar Treats: Main Uses and Benefits

This medication is commonly used as a foundational part of symptomatic management for Parkinson's disease and certain forms of parkinsonism. It is a relevant option for easing the impact of core motor symptoms and is used to address symptom groups that may become intense or disruptive. These include profound slowness of movement (bradykinesia), muscular rigidity (stiffness), and the characteristic resting tremor.

Levodopa is generally applied when symptoms progress to a point of noticeable functional disability, interfering with routine tasks. It assists with managing these manifestations, which supports the ability to move with greater speed and range. This supports patients in maintaining a greater degree of physical autonomy and supports general well-being during symptomatic phases.

In the context of long-term management of this progressive disorder, the medication plays a role in managing symptom control throughout the day and is helpful in situations where multiple symptoms occur together. This is relevant for managing motor fluctuations, which are symptomatic episodes that may intensify temporarily.

Quick Fact: Symptomatic Support for Bradykinesia and Rigidity

“The therapeutic benefit is focused on supporting motor function and assists with maintaining a sense of stability when symptoms are more noticeable.”

Regulatory References

  1. MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Dopar (Levodopa)

The official population eligibility for levodopa (Dopar) is strictly defined by government regulatory agencies, outlining who is permitted, restricted, or absolutely prohibited from using the medication.

Classification Population/Condition Regulatory Status
Contraindicated Narrow-angle glaucoma Must not use
Contraindicated History of malignant melanoma or undiagnosed suspicious skin lesions Must not use
Contraindicated Concurrent use of nonselective MAO inhibitors Must not use
Restricted Use History of peptic ulcer disease Use with caution (risk of hemorrhage)
Restricted Use Severe cardiovascular, pulmonary, renal, or hepatic disease Use with caution and monitoring
Not Recommended Pediatric patients (under 18 years) Safety and efficacy not established
Conditional Use Pregnancy and Lactation Benefit must outweigh potential risk; levodopa is excreted into human milk

Eligibility is established for adult patients with levodopa-responsive parkinsonism. While elderly patients are generally included, official documents advise closer monitoring due to potential increased sensitivity and the prevalence of age-related organ issues. Patients with major psychotic disorders are generally not treated with this medication due to the risk of exacerbating their condition. This structure defines the approved adult population while strictly excluding groups with specific medical histories or physiological states.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Dopar (Levodopa/Carbidopa) primarily addresses enzyme inhibition, transport competition, and pharmacodynamic effects, based on regulatory labeling.

Contraindicated and Restricted Combinations

Co-administration with nonselective Monoamine Oxidase (MAO) Inhibitors is strictly contraindicated due to the risk of a hypertensive crisis, requiring a minimum two-week separation period after discontinuing the MAOI. Similarly, use with Sympathomimetic Amines may result in serious cardiac adverse effects.

Clinically Significant Interactions

Interacting Product Category Interaction Mechanism and Effect
Antipsychotics (e.g., Phenothiazines) Block dopamine receptors, potentially reducing the effectiveness of Dopar.
Antihypertensive Drugs Increased risk of orthostatic hypotension; requires monitoring and potential dose adjustment of the antihypertensive agent.
COMT Inhibitors (e.g., Entacapone) Increases the plasma concentration (AUC) of levodopa by inhibiting its peripheral breakdown.
Iron Salts/Supplements Interferes with levodopa/carbidopa absorption in the gut, reducing systemic exposure.
High-Protein Meals Large Neutral Amino Acids (LNAAs) compete for transport into the bloodstream and the brain, potentially lowering levodopa effectiveness.

Timing and Population Considerations

The regulatory profile notes that iron supplements may require separation in dosing time to mitigate reduced absorption. Furthermore, plasma concentrations of levodopa are generally noted to be higher in elderly patients, which may increase the potential for concentration-dependent interactions.

Mechanism of Action

How Dopar Works — Mechanism of Action

This mechanism operates via synergistic pharmacological action to modulate the dopaminergic neurotransmitter system. The ingredient Carbidopa acts as an irreversible inhibitor of the enzyme Aromatic L-amino acid decarboxylase ( AADC) in peripheral tissues. This peripheral enzyme inhibition protects the precursor molecule, Levodopa, from premature metabolic breakdown, allowing a greater amount to remain available for transport across the blood-brain barrier ( BBB) via the LAT1 transporter.

Once inside the central nervous system ( CNS) neurons, Levodopa undergoes a prodrug conversion catalyzed by AADC, yielding the active neurotransmitter, dopamine. The resulting increase in functional dopamine concentration leads to the indirect agonism of postsynaptic dopamine receptors ( D1– D5) within the CNS motor circuits. This augmented signaling allows the system to process signals associated with muscle tone and movement control, thereby modulating physiological control over muscle action.

Dosage and Administration Information

Official Administration Guidelines for Dopar

Levodopa co-formulations (historically Dopar) are administered through two primary approved routes: oral intake (using immediate-release or extended-release tablets and capsules) and enteral infusion directly into the jejunum for advanced management.

Dosage and Titration Schedule

Treatment generally begins with a low starting dose, such as 25 mg carbidopa / 100 mg levodopa, taken orally three times per day. The maintenance dosage is highly individualized but must be gradually adjusted, or titrated, over time according to the prescribed regimen to reach the lowest effective amount. A maximum daily dose is specified that should not be exceeded, such as up to eight 25 mg/100 mg immediate-release tablets. Patients converting from levodopa monotherapy must wait at least 12 hours after the last dose before beginning a co-formulation.

Administration Timing and Preparation

Oral doses must be taken multiple times daily (divided doses). The medication may be taken with or without food; however, high-protein or high-calorie meals may reduce or delay the absorption of levodopa. Extended-release tablets and capsules must be swallowed whole and should never be crushed, divided, or chewed, as this alters the drug's intended release profile. For the enteral route, the suspension is administered as a 16-hour continuous infusion cycle during waking hours, and the drug cassette must be brought to room temperature before use. The medication is generally not recommended for use in patients under 18 years of age.

Recent Clinical Evidence

Research Evidence Overview for Levodopa (Dopar)

Evidence for Use in Parkinson's Disease and Parkinsonism

Research examining levodopa (the active ingredient in Dopar) has been studied for the symptomatic management of Parkinson’s disease and related conditions known as parkinsonism. The knowledge base is comprehensive, built upon decades of pharmacological studies that include Randomized Controlled Trials (RCTs), large overviews known as Meta-analyses, and wide-ranging Observational Studies.

These studies involved adults experiencing functional limitations due to the condition. Researchers examined outcomes related to core movement symptoms, specifically slowness of movement (bradykinesia) and muscular rigidity (stiffness). Findings from this extensive research describe patterns observed in the studies that led to the clinical recognition of levodopa as a core compound for addressing primary motor symptoms.

Studies on Motor Fluctuations and Advanced Symptom Management

Levodopa was also evaluated in contexts related to managing motor fluctuations. These fluctuations are changes in symptom control that can cause episodic or acute changes where symptoms become more noticeable, which are conditions characterized by fluctuating or episodic manifestations.

Research in this area often involved RCTs and Observational Studies focusing on patients with more advanced disease, including those on long-term levodopa therapy. These studies examined outcomes related to the frequency and duration of the periods when symptoms were less controlled. Findings describe patterns observed in the studies that research has explored in the context of symptom control during these temporary episodes.

Key Limitations and Areas of Research Uncertainty

While the evidence base is broad, the long-term effects are not fully established across all outcomes, especially when considering the continuous changes caused by a progressive disorder. Many clinical trials focused on specific symptomatic changes often had follow-up durations that were limited to a few weeks or months. Additionally, data for certain groups remain insufficient. For instance, the complex studies related to motor fluctuations often involve narrow populations of patients already on long-term therapy, meaning results apply only to the populations studied.

Key Studies & References Levodopa: Drug Information

How should Dopar be stored and disposed of?

How to Store and Dispose of Dopar (Levodopa/Carbidopa)

Official regulatory guidelines define strict requirements for the storage and disposal of this medication, focusing on stability and environmental safety.

Requirement Area Official Instructions
Storage Temperature Store at controlled room temperature (typically 25^circC/77^circF), permitting excursions between 15^circC and 30^circC.
Environmental Protection Keep the product in the original container with the lid tightly closed. It must be protected from light and moisture.
Child Safety As with all medicines, it must be stored out of reach of children.
Disposal Do not flush unused or expired medication down the toilet or place it in household trash. Return the product to a mathbfpharmacist or an approved drug take-back program for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagTaiwan

Equivalent of Dopar found in:

A-Z Index: